Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ovid TherapeuticsOVID +1.89%34 Operating Cash Flow per Share is $-0.50 as of Jun. 2026. GuruFocus rates OVID with a GF Score™ of 34/100 and a GF Value™ of $0.88 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,130 Biotechnology companies, Ovid Therapeutics ranks worse than 54.87% on this metric.
Ovid Therapeutics's operating cash flow per share for the
three
months ended in Jun. 2026 was $-0.09.
Ovid Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $-0.50.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 12.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Ovid Therapeutics's Operating Cash Flow per Share or its related term are showing as below:
OVID'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -87.6 Med: 11.3 Max: 18.4
Current: 12.8
During the past 11 years, Ovid Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 18.40% per year. The lowest was -87.60% per year. And the median was 11.30% per year.
OVID's 3-Year OCF Growth Rate is ranked worse than 54.87% of 1130
companies
in the Biotechnology industry
Industry Median: 16.85
vs OVID: 12.80
Ovid Therapeutics Operating Cash Flow per Share Related Terms
Ovid Therapeutics Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Ovid Therapeutics's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovid Therapeutics Operating Cash Flow per Share Chart
OVID vs ZURA, ARTV, SCTX: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Ovid Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovid Therapeutics Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Ovid Therapeutics's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.50
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $-0.50 mean?
Ovid Therapeutics (OVID) has a Operating Cash Flow per Share of $-0.50 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Ovid Therapeutics and its competitors. According to the industry distribution chart, Ovid Therapeutics ranks #620 out of 1130 companies in the Biotechnology industry, placing it in the top 54.9%.
Is Ovid Therapeutics' Operating Cash Flow per Share too high?
Ovid Therapeutics' current Operating Cash Flow per Share is $-0.50. Based on the distribution chart, Ovid Therapeutics ranks #620 out of 1130 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ovid Therapeutics has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' Operating Cash Flow per Share compare to ZURA and ARTV?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #620 out of 1130 companies for Operating Cash Flow per Share. This places Ovid Therapeutics in the lower half of its industry. The industry median Operating Cash Flow per Share is 16.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 16.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Ovid Therapeutics and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 16.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovid Therapeutics's current Operating Cash Flow per Share is $-0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.88, compared to a current price of $2.67 — trading 203.4% above its estimated fair value. The current Operating Cash Flow per Share is $-0.50. Ovid Therapeutics' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current Operating Cash Flow per Share is $-0.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ovid Therapeutics (OVID) Overvalued in 2026?
Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be overvalued.
The current stock price of $2.67 is trading 203.4% above its estimated GF Value™ of $0.88.
GuruFocus considers Ovid Therapeutics to be Significantly Overvalued.
Key valuation signals for OVID:
Operating Cash Flow per Share: $-0.50
GF Value™: $0.88 vs. price of $2.67 (203.4% above fair value)
No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
34GF Score
Get the complete analysis for OVID
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVID has been successfully added to your 
